Sandoz - A Global Leader

March 2013

Nick Haggar Head Sandoz Africa, Middle East and Western Europe

This is the first dummy chapterSandoz a Global Leader

2 | Together Growing Faster - Sandoz and Celesio | October 10th, 2012

Environment Patient needs Novartis portfolio

Sandoz is a Novartis Group Company

2011 salesUSD billion

Full rangeof healthcareoptions

Innovative medicines

Prevention

Affordable options

Self-care

Pharmaceuticals

Sandoz – Generics

Consumer Health (OTC, Animal Health)

Vaccines and Diagnostics

Eye Care (Alcon, CIBA VISION)

32.5

9.5

4.6

2.0

10.0

Novartis’ mission is to care for and cure patients

In 2011, Novartis treated and protected more than 1 billion patients

around the world with our products and Sandoz medicines reached over

400 million patients

Sandoz is a global leader in generics

1 Pro forma by including all acquired companiesNote: Figures reflect sales and ROS for generics business only, including API and excluding originator (e.g. Copaxone) and proprietary business (e.g. Women’s Health) Note: All trademarks, logos and pictures are the property of the respective ownerSource: Company annual and quarterly reports, except Actavis figures estimated based on IMS

2011 generics sales1

USD million

2,432

2,273

10,196

3,320

2,313

9,473

2,358

5,559

2,126

1,876

Present in 140 countries

~25,000 employees worldwide

Portfolio of ~1,100 compounds and >23,500 SKUs

Rich pipeline with >800 projects

Leader in differentiated generics

Biosimilars pioneer

Sandoz operates in 140 countries globally

Subsidiaries

Representative offices

* Sample Sandoz manufacturing and development sites.

Production*

Development*

Wilson

Cambe/ Taboao

Buenos Aires

Gebze Turbhe

Strykow

Zhongshan

Kaminoyama

Barleben

Boucherville

Broomfield

Unterach

Kalwe

Holzkirchen Rudolstadt

Kundl / Schaftenau

Ljubljana / Mengeš

Spartan Jakarta

Candelaria

Sandoz has an industry-leading breadth of technologies

Inhalers

Patches/transdermals/ thin films

Innovativesolid formulations

Implants

Biosimilars

APICytotoxics

Hormones

Lyophilization

Injectables

Ophthalmics

Dermatology

Anti-Infectives: Sandoz is the leading Gx player

GlaxoSmithKline

0.7Bayer

Medicis 0.8

Daiichi Sankyo 2 0.9

Johnson & Johnson 1.0

Merck & Co. 1.2

Teva 1.3

Sanofi 2 1.3

Sandoz 1.7

1.7

Pfizer 3.7

Total anti-infectives sales USD bn (FY 2011)

-6%

-4%

-5%

-5%

-2%

+4%

-8%

-12%

+22%

-25%

CAGR1 Percent (2009-11)

Source: IMS, global market, anti-infectives defined as J1 (antibacterials)

GxOriginator

1 Growth rate at constant currency rate2 Incl. Generic business

This is the first dummy chapterSandoz in Africa

Commitment and Growth in Africa

Minister of Industry and Trade, Egypt

World Economic Forum, Addis Ababa

Minister of Health, Ethiopia

AU-UNIDO Conference on Diversified Economy and Manufacturing, Addis Ababa

Wide range of bilateral meetings

•4 Ministers

•7 NGOs (Bill & Melinda Gates Foundation, Director-General of Red Cross, ...)

•Private companies (Philips, Coca Cola, Merck, ...)

•Development organizations (GIZ, US African Development Foundation, ...)

Wide range of bilateral meetings

•Local manufacturers from Ethiopia, Kenya, Botswana, Sierra Leone, ...

•UN, WHO, GIZ, British Embassy, German Embassy, Swiss Embassy

5 joint projects to improve patient’s life - Zambia Example

Cardiovascular Academy

Rheumatic Heart

Disease

Health shops

Build high quality, affordable portfolio

Zambora Project

Focus Areas

Quality

Regulatory

Distribution

Affordability

Partnerships

REGIONAL FOCUS: GROWTH OPPORTUNITIES FOR PHARMA COMPANIES

IN THE WEST AFRICAN MARKET DR YAW ADU GYAMFI, CEO, DANADAMS PHARMACEUTICAL INDUSTRIES

NICK HAGGAR, HEAD, WESTERN EUROPE, MIDDLE EAST & AFRICA, SANDOZ

MODERATOR: DR VINCE S. THOMAS, MANAGING DIRECTOR, V.S THOMAS GLOBAL HEALTH STRATEGY CONSULTING